Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795281 | 0.84 | TRPV4 (0.43) | PGRTRPV4RXFP1PDE5AAVPR1B | |
| SCHEMBL75146 | 0.84 | KMT2A (0.50) | PGRTRPV4RXFP1PDE5AAVPR1B | |
| SCHEMBL1788080 | 0.84 | PGR (0.40) | PGRTRPV4AVPR1BAURKB | |
| SCHEMBL16837188 | 0.84 | PGR (0.40) | PGRTRPV4AVPR1BAURKB | |
| SCHEMBL1464210 | 0.81 | KMT2A (0.40) | PGRALDH1A1AURKBNPSR1KMT2A | |
| SCHEMBL4510489 | 0.80 | RXFP1 (0.42) | PGRTRPV4RXFP1L3MBTL1ALDH1A1 | |
| SCHEMBL1801335 | 0.77 | RXFP1 (0.40) | PGRTRPV4RXFP1AVPR1BL3MBTL1 | |
| SCHEMBL73939 | 0.77 | RXFP1 (0.38) | PGRTRPV4RXFP1AVPR1BL3MBTL1 | |
| SCHEMBL1801337 | 0.76 | LMNA (0.38) | PGRTRPV4RXFP1L3MBTL1ALDH1A1 | |
| SCHEMBL16837191 | 0.74 | SNCA (0.46) | PGRAVPR1BALDH1A1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202870-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090215790-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| EP-1866304-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1861390-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100080-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100081-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215790-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | PGR 317/4885TRPV4 1606/4885RXFP1 61/4885 |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | PGR 449/4885TRPV4 1033/4885RXFP1 65/4885 |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | OXTR, AVPR2, AVPR1B | PGR 449/4885TRPV4 1033/4885RXFP1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.